The evidence of the efficacy of preoperative medical treatment with danazol, gonadotrophin releasing-hormone agonists (GnRHa) or progestins in facilitating surgery and improving the long-term results of myomectomy, hysteroscopic metroplasty and endometrial resection has been reviewed. Sixteen randomized and non-randomized controlled clinical trials, published in the English literature between 1990 and 1996, were identified. In all studies comparing GnRHa or danazol versus no treatment, fluid absorption during surgery was less in subjects who underwent medical treatment independently of the drug used and the type of intervention, the reduction ranging from 142 to 572 ml. A reduction in operating time (between 2 and 25 min) was observed in both the danazol and GnRHatreated groups in comparison with untreated controls, regardless of the type of operation (endometrial resection, myomectomy or metroplasty). With regard to long-term results, amenorrhoea tended to be more frequent in patients who received GnRHa: the pooled odds ratio (OR) of amenorrhoea for GnRHa-treated women compared with untreated controls was 2.0 [95% confidence interval (CI), 1.1-3.8]. In studies comparing GnRHa with danazol, no marked differences were observed in mean operating time, but the OR of amenorrhoea at 6-12 months after surgery was 1.9 (95% CI 1.0-3.3).
Introduction
In the past decade, interest has grown in hysteroscopic surgery of myomas. Endoscopic myomectomy and metroplasty have been used to treat submucosal myomas and septate uteri. In addition, the technique of endometrial resection has been developed and in many centres is now the treatment of choice for dysfunctional menorrhagia (Gannon et al., 1991) .
According to many authors, pretreatment with drugs which reduce endometrial thickness or the volume of myomas, such as danazol and gonadotrophin-releasing hormone agonists (GnRHa) (Donnez et al., 1996; De Leo et al., 1997) , may facilitate hysteroscopic surgery and could also-particularly in the case of endometrial resection-improve the long-term results. The aims of medical treatment as preparation for hysteroscopic surgery are to improve the operator's visibility by limiting blood loss, reduce fluid absorption and, in the case of endometrial resection, facilitate radical removal of the uterine mucosa, thus increasing the success rate. Moreover, as patients need not necessarily be operated on in the early proliferative phase, preoperative treatment also has a practical benefit in that it allows surgery to be performed at any time.
This paper reviews the main evidence in the literature assessing the efficacy of preoperative medical treatment in facilitating hysteroscopic surgery and improving the longterm results of myomectomy, hysteroscopic metroplasty and endometrial resection.
Materials and methods
The articles included in this review are randomized and nonrandomized controlled clinical studies, published in English between 1990 and 1996, on the efficacy of treatment with danazol, GnRHa or progestins as preparation for myomectomy, metroplasty or endometrial resection (Donnez et al., 1990; Goldfarb, 1990; Brooks et al., 1991; Magos et al., 1991; Petrucco and Fraser, 1992; Serden and Brooks, 1992; Perino et al., 1993; Vercellini et al., 1993 Vercellini et al., , 1994 Vercellini et al., , 1996 Sutton and Ewen, 1994; Tantini et al., 1994; Alford and Hopkins, 1996; Fedele et al., 1996; Fraser et al., 1996; Garry et al., 1996) . They were identified by a computerized (MEDLINE) search of the literature and from references of publications on the topic.
Data analysis
In the analysis of dichotomous variables we used standard methods to compute odds ratios (OR) and corresponding 95% confidence intervals (CI) and for combining information from 2ϫ2 tables derived from the various studies. The expected number of events in the cases treated and not treated and the variance (V) between observed (O) and expected (A) cases have been calculated using the MantelHaenszel procedure (Mantel and Haenszel, 1959) . It is assumed that if the treatment did not show efficacy, the value (O-A) with variance V (or standard error, αV) would differ from O only by random variability. On the other hand, if the treatment were to be active, the value (O-A) would have been positive and, although in the single studies this trend may be limited or may not be evident based on the random effect, this should become evident whenever the grand total (GT) of the differences (O-A) obtained in the single studies were to be analysed. Conversely, if the treatment was not effective, the GT would differ from zero only for the random effect, with the variance equal to the sum of the variances of the single studies (SSV) and standard error, αSSV. Furthermore, taking into account that the effect of the treatment is not heterogeneous among single studies, then the OR of the treatment effect has been calculated in the following way: exp (GT/SSV) with CI of 95% ϭ exp (GT/SSV) Ϯ 1.96 SSV. It should be emphasized that these statistical techniques do not assume that subjects of one study can be compared directly with those of Magos et al. (1991) NR 20 (DUB in women with Danazol 600 mg/day for 6 weeks patent tubes who required myomectomy for which operating time was Ͼ40 min) Petrucco and Fraser (1992) NR 90 (DUB) Danazol 600 mg/day for 3 weeks Petrucco and Fraser (1992) NR 24 (DUB) Goserelin 3.6 mg Serden and Brooks (1992) NR 102 (DUB) Leuprolide acetate 7.5 mg Serden and Brooks (1992) NR 72 (DUB) Danazol 600-800 mg/day for 6 weeks Perino et al. (1993) NR 56 (DUB) Leuprolide acetate 3.75 mg 58 (submucous myomas Ͻ3 cm) 79 (septate uteri) Tantini et al. (1994) NR 122 (septate or subseptate Triptorelin for 3 months uteri) Vercellini et al. (1993) NR 22 (hysteroscopic metroplasty Goserelin 3.6 mg for double uterine cavity) Vercellini et al. (1994) NR 55 (DUB) Goserelin 3.6 mg for 2 months Vercellini et al. (1996) R 63 (DUB) Goserelin 3.6 mg for 2 months DUB ϭ dysfunctional uterine bleeding. a NR ϭ non-randomized; R ϭ randomized.
another study. These techniques are based entirely on the comparison of treatment of patients treated with a drug in one study with patients treated with a comparative drug in the same study.
Results
We identified a total of nine studies that compared medical treatment with danazol or GnRHa (goserelin, leuprolide acetate, triptorelin) with no treatment in preparation for hysteroscopic endometrial resection, myomectomy or metroplasty (Table I) . Only one study was described as randomized and indicated the method of allocation to treatment; the others were comparative studies in which the modality of treatment allocation was not specified. Danazol was used in three studies (Magos et al., 1991; Petrucco and Fraser, 1992; Serden and Brooks, 1992) . Goserelin was used in five studies (Donnez et al., 1990; Petrucco and Fraser, 1992; Vercellini et al., 1993 Vercellini et al., , 1994 Vercellini et al., , 1996 , leuprolide acetate in two (Serden and Brooks, 1992; Perino et al., 1993) and triptorelin in one (Tantini et al., 1994) . Most of the studies considered medical treatment in preparation for endometrial resection; in two studies it was given before myomectomy and in three before metroplasty. Mean intraoperative fluid absorption reported in the studies are shown in Table II .
One study (Magos et al., 1991) analysed the efficacy of danazol in reducing intraoperative fluid absorption in endometrial resection: its result suggests a reduction in fluid absorption (-572 ml) in women treated with danazol compared with untreated women. Two studies reported the efficacy of goserelin in reducing fluid absorption in endometrial resection: in both, fluid absorption was less in those subjects who underwent goserelin treatment. One study (Perino et al., 1993 ; not shown in Table II ) reported values of mean fluid infusion (but not absorption) in women treated with leuprolide acetate (3600 ml) versus untreated controls (7400 ml) in preparation for endometrial resection.
One study (Donnez et al., 1990 ) reported on treatment with goserelin before myomectomy, the mean fluid absorption being 330 ml in treated women and 750 ml in untreated controls.
With regard to metroplasty, one study (Vercellini et al., 1993) analysed the effect of goserelin in reducing fluid absorption, the mean fluid absorption being 340 ml in treated women and 620 ml in those not treated. In the study of Tantini et al. (1994) , in which subjects were considered with septate or subseptate uteri undergoing hysteroscopic metroplasty, and treated with triptorelin, absorption was reduced only in treated women with complete septate uteri.
The results with regard to operating time are shown in Table III , all studies reporting a reduction in mean operating time in treated patients. In the case of endometrial resection, the reduction in operating time was observed in both the danazol and GnRHa-treated groups. Perino et al. (1993) analysed the effect of leuprolide acetate in reducing operating time during myomectomy, the mean operating time being 25 min in treated women and 38 min in those not treated. With regard to metroplasty, one study analysed the effect of goserelin (Vercellini et al., 1993) and one of leuprolide acetate (Perino et al., 1993) ; in both, the mean operating time was shorter among treated women than untreated women, though the difference was limited (3-6 min).
The long-term results (amenorrhoea rate at 1 year) of four studies in which subjects did or did not receive medical treatment before endometrial resection are shown in Table IV . Two studies analysed the effect of danazol versus no treatment in preparation for endometrial resection with regard to the frequency of postoperative amenorrhoea. No difference was seen in one study (Serden and Brooks, 1992) , while in the study by Petrucco and Fraser (1992) no difference emerged when the endometrial resection was made using a resectoscopic/cutting loop. Although an increased frequency of amenorrhoea was seen in women treated with the roller ball, this was not statistically significant (OR 3.5, 95% CI 0.6-19.5). One year after treatment amenorrhoea tended to be more frequent in patients who received GnRHa. Taken together, the results of three studies in which GnRHa were used showed the overall OR of amenorrhoea to be 2.0 (95% CI 1.1-3.8).
The main characteristics of the eight studies (six randomized, two non-randomized) that compared preoperative danazol with GnRH agonist treatment are shown in Table V . One study (Fedele et al., 1996) reported 30 subjects who underwent hysteroscopic metroplasty, while the other seven reported subjects who underwent endometrial resection, though in one study (Brooks et al., 1991) only histopathological rather than clinical end-points were evaluated. The small study on metroplasty revealed no marked differences between preoperat-2594 ive treatment with either leuprolide acetate and danazol in terms of intraoperative bleeding or subjective difficulties of the surgeon (mean scores 0.5 Ϯ 0.5 versus 0.6 Ϯ 0.6 and 0.9 Ϯ 0.7 versus 0.3 Ϯ 0.5 respectively, based on scores for which none ϭ 0, moderate ϭ 1, and severe ϭ 2). There was also no difference in the incidence of postoperative intrauterine septal adhesions (0 versus 0, data not shown).
No marked differences were observed between the effect of GnRHa and danazol in terms of mean operating time, though the information provided was limited; in some cases numerical data were not provided, with only general comments indicating no difference, and details of intraoperative fluid deficit not available. In comparing women treated with GnRHa versus Goldfarb (1990) No 35 Danazol 800 mg/day for 30 days Leuprolide 0.5 mg Brooks et al. (1991) Yes 25 Danazol 600-800 mg for 6 weeks No clinical data reported but Leuprolide acetate 7-5 mg depot only the indication that for 2 months leuprolide induced a greater endometrial inhibition than danazol or progestin Petrucco and Fraser (1992) No 86 (43 operated with resectoscope, Danazol 600 mg for 3 weeks 43 with roller ball Goserelin 3.6 mg Sutton and Ewen (1994) Yes 110 Danazol 800 mg/day for 2 months Goserelin 3.6 mg for 2 months Alford and Hopkins (1996) Yes 30 Danazol 800 mg Leuprolide acetate 3.75 mg for 1 month Garry et al. (1996) Yes 139 Danazol 800 mg for 4 or 8 weeks Goserelin 3.6 mg for 1 or 2 months Fraser et al. (1996) Yes 60 Danazol 400 mg for 6 weeks Goserelin 3.6 mg for 2 months danazol in preparation for endometrial resection, the OR for amenorrhoea at 6-12 months was 1.9 (95% CI 1.0-3.3) (Table VI) . Only two controlled clinical studies were identified that compared the use of a progestin (depot medroxyprogesterone acetate) with other treatments in inducing endometrial atrophy in preparation for endometrial resection (Serden and Brooks, 1992; Alford and Hopkins, 1996) . No marked differences were observed in the amenorrhoea rate at 6-12 months, though the number of women receiving progestin treatment was very small.
Discussion
This review of controlled clinical studies on the efficacy of medical treatment in facilitating surgery and improving the long-term results of endometrial resection, myomectomy and hysteroscopic metroplasty shows a reduction of intraoperative fluid deficit in treated subjects. The reduction was obtained with both danazol and GnRHa. Furthermore, among treated women, all studies showed a reduction in operating time which was independent of both the drug used and the type of surgery; however, such reduction was limited and clinically negligible. Sutton and Ewen (1994) No difference a Not reported Alford and Hopkins (1996) Not reported -12 (50): 24 3 (50): 6 1.0 Garry et al. (1996) 16 22 18 (24): 74 4 (6): 65 4. 6 Fraser et al. (1996) 20 20 20 (74) Few studies presented long-term results, and these were not completely consistent, especially with regard to the amenorrhoea rate at 6-12 months after endometrial resection. However, amenorrhoea tended to be more frequent in women given GnRHa. This literature review did not identify any marked difference between danazol and GnRH agonists in terms of mean operating time, although the rate of amenorrhoea at 6-12 months tended to be higher in GnRHa-treated women. Similarly, very few data are available on treatment with progestins, and conclusions on the efficacy of this approach still cannot be drawn.
In interpreting these results, some limitations of the published studies must be borne in mind. First, possible publication bias may influence the results of quantitative reviews of the literature. Indeed, positive studies tend to be over-represented in the literature (Rennie and Flanagin, 1992) as the decision to publish data is often based on the informal observation of favourable findings: this 'censoring' by authors represents a drawback of this type of critical review of the literature. Moreover, most of the comparative studies considered were not randomized, which constitutes a well-recognized limit.
In this review, preoperative treatment was shown to result in reduced fluid deficit and operating time, though such reductions were of questionable clinical relevance. Indeed, reducing intravasation by 100-150 ml may not influence the risk of severe complications which ensue only when the fluid deficit is Ͼ1 l. Likewise, reducing operating time by a few minutes is not clinically important.
Intrauterine visibility would be improved in woman treated before surgery and this should facilitate complete endometrial resection. Otherwise, the treatment should cause the mucosa partly to disappear and thus complete mucosal resection could not be effected. These different mechanisms may be the cause(s) of either decreased or increased failure of treatment, i.e. the recurrence of menorrhagia. In this literature review the frequency of postoperative amenorrhoea was approximately twice that in women treated with GnRHa than in untreated women, though these findings were based on very few cases. For this specific end-point the present analysis considers the results of the identified studies together, independently of the 2596 type of GnRHa administered, as the mechanism of action and efficacy of such treatments appears almost identical. Moreover, a separate analysis for the different GnRHa did not reveal important differences.
Another potential advantage of medical treatment is that patients given medical treatment preoperatively can be operated on at any time-an organizational benefit that is far from negligible.
Recently, it has been suggested that the advantage of a reduced fluid deficit during endometrial resection may be greater in patients with adenomyosis (Vercellini et al., 1996) . Although routine preoperative screening of all patients for adenomyosis is performed universally, mainly for reasons of cost and organization, the ability to identify those subjects who stand to benefit most from such medical treatment represents an important aspect of clinical research.
In conclusion, preoperative medical treatment facilitates endometrial resection, though whether it has such beneficial influence on long-term results is less well defined and requires further investigation. The identification of subjects who could derive the most benefit from such treatment is also important.
